Ardelyx Revenue Rises 19% to $125.5 Million

The drugmaker reported third-quarter 2026 results driven by growth in its IBSRELA and XPHOZAH products.

Updated on Nov. 3, 2026 in Economic Indicators

Isometric editorial illustration of stainless-steel bioreactor vessels linked by coiled tubing in a plain industrial hall, rendered in oxblood, teal, and mustard. — Ardelyx reported third-quarter 2026 revenue of $125.5 million, up 19 percent, driven by IBSRELA and XPHOZAH sales growth. AI Illustration. Upload story photo >

Ardelyx reported total product revenue of $125.5 million for the quarter ended September 30, 2026, up 19% year-over-year. IBSRELA revenue reached $96.3 million, rising 23%, while XPHOZAH revenue was $29.2 million, up 7%.

Why it matters

The results show continued commercial uptake of Ardelyx's two approved products, with the company holding $285.3 million in cash and investments as of quarter end. Management also completed enrollment ahead of schedule in its Phase 3 ACCEL trial for chronic idiopathic constipation.

Ardelyx reported third-quarter 2026 total product revenue of $125.5 million, up 19% year-over-year, with IBSRELA contributing $96.3 million (up 23%) and XPHOZAH $29.2 million (up 7%). Topline results from the ACCEL Phase 3 trial are not expected until the second half of 2027.

The players

Ardelyx

Ardelyx is a Waltham, Massachusetts-based biopharmaceutical company that markets IBSRELA and XPHOZAH, both built on the drug tenapanor.

The details

Ardelyx attributed IBSRELA revenue growth to increases in total writers and total prescriptions. Research and development expenses rose to $25.2 million from $18.1 million a year earlier, primarily reflecting investment in the ACCEL trial, while selling, general and administrative expenses reached $93.9 million, up from $83.6 million.

September 30, 2026: Quarter ended and cash position reported
November 3, 2026: Quarterly results released and conference call held
November 10, 2026: USPTO scheduled to issue patent No. 12,788,750
Second half of 2027: Expected topline data from the ACCEL Phase 3 trial
December 6, 2041: Expiration date of patent No. 12,788,750

Market Dynamics

IBSRELA, the tenapanor-based treatment for irritable bowel syndrome with constipation, continues to drive Ardelyx's growth, with its 23% year-over-year revenue increase outpacing the 7% gain for XPHOZAH. Ardelyx's stated long-term goal of $1 billion in annual IBSRELA revenue frames the current quarter as a step along that path.

For shareholders, the quarter's $0.7 million net loss, or $(0.00) per share, included $15.1 million in share-based compensation, indicating that stock-based pay weighed heavily on reported results. Investors tracking the stock will focus on whether revenue growth continues to outpace operating spending.

The takeaway

Ardelyx's revenue growth is concentrated in IBSRELA, so the company's near-term financial trajectory depends heavily on that single product's continued prescription and writer growth. Readers tracking the company should watch for the ACCEL trial readout in 2027.

What happens next

Ardelyx expects topline data from its Phase 3 ACCEL trial in the second half of 2027, and patent No. 12,788,750 is scheduled to be issued by the USPTO on November 10, 2026.